Jamax-S (Alendronate Sodium Trihydrate)

Alendronate sodium trihydrate binds to bone mineral at sites of active remodeling. When osteoclasts attach to the drug‑coated surface, it inhibits the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and leading to reduced osteoclast activity and decreased bone resorption.

The specific dose of Jamax‑S is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Healthcare professionals follow established guidelines but must individualise the regimen for each patient.

Safety of alendronate during pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and the decision should be made by a qualified healthcare provider.

To order Jamax‑S, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Jamax‑S (alendronate) is a first‑generation bisphosphonate with a well‑established efficacy profile for osteoporosis and Paget's disease. Compared with newer agents such as risedronate or zoledronic acid, alendronate is typically taken orally once weekly or monthly, whereas some alternatives may be daily or intravenous, offering different convenience and adherence considerations.

Jamax‑S should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight or excessive humidity.

Jamax‑S is taken orally with a full glass of plain water on an empty stomach, first thing in the morning, at least 30 minutes before any food, drink, or other medication. After taking the dose, the patient should remain upright for at least 30 minutes to reduce the risk of esophageal irritation.

Serious adverse events include esophageal ulceration or erosion, osteonecrosis of the jaw, atypical femur fractures, severe hypersensitivity reactions, and acute renal impairment. Patients should promptly report persistent throat pain, jaw discomfort, unexplained bone pain, or signs of an allergic reaction to their healthcare provider.

Jamax‑S is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders that delay emptying, known hypersensitivity to alendronate or any excipients, and those who cannot remain upright for 30 minutes after dosing. Clinicians should assess each patient’s medical history before prescribing.